Renal Cancer - Results from #1380

GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment. July 26, 2022

Comparison of perioperative outcomes following transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a propensity-matched analysis of VCQI database. July 25, 2022

Systematic Investigation of Immune-Related lncRNA Landscape Reveals a Potential Long Non-Coding RNA Signature for Predicting Prognosis in Renal Cell Carcinoma. July 25, 2022

Analysis of Pyroptosis-Related Immune Signatures and Identification of Pyroptosis-Related LncRNA Prognostic Signature in Clear Cell Renal Cell Carcinoma. July 22, 2022

Association Between Metabolic Syndrome and Risk of Renal Cell Cancer: A Meta-Analysis. July 22, 2022

The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. July 21, 2022

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. July 21, 2022

Development of a Novel Sphingolipid Signaling Pathway-Related Risk Assessment Model to Predict Prognosis in Kidney Renal Clear Cell Carcinoma. July 20, 2022

Tivozanib for the treatment of advanced renal cell carcinoma. July 20, 2022

In the Phase III IMmotion151 Trial of Metastatic Renal Cell Carcinoma the Easy-to-Implement Modified Glasgow Prognostic Score Predicts Outcome More Accurately than the IMDC Score July 19, 2022

Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma. July 19, 2022

A novel nomogram can predict pathological T3a upstaged from clinical T1a in localized renal cell carcinoma. July 19, 2022

COLGALT1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of ceRNA networks. July 18, 2022

Safety and efficacy of stereotactic ablative radiotherapy for renal cell cancer: 24-months results of the RSR1 phase I dose escalation study. July 18, 2022

SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma. July 15, 2022

Phytochemicals for the Prevention and Treatment of Renal Cell Carcinoma: Preclinical and Clinical Evidence and Molecular Mechanisms. July 15, 2022

Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy. July 14, 2022

Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. July 14, 2022

Recommendations for the management of advanced and metastatic renal cell carcinoma: joint consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. July 14, 2022

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. July 13, 2022

Page 70 of 455